ABBOTT LABS

Abbott Laboratories' institutional footprint — 3,400+ holders and $148B in reported value — reflects the market's treatment of Abbott as the most diversified large-cap healthcare name in the S&P 500. Unlike pure-play pharmaceutical companies that derive the bulk of revenue from drug pipelines, or pure-play device companies dependent on procedural volume, Abbott's three-pillar model (diagnostics, medical devices, established pharmaceuticals) gives institutional allocators a single name that captures multiple healthcare sub-themes simultaneously. The top-holder set includes the usual core-holdings suspects — Vanguard, BlackRock, State Street — alongside healthcare-specialist active managers who have held Abbott through multiple product cycles. The structural read is that institutional investors use Abbott as a healthcare-sector core rather than a thematic bet on any single sub-industry, which is why the holder base is both deep and durable.